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Recently, the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) 7 and the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial 8, 9 demonstrated that CRT, in combination with optimal medical therapy (with or without defibrillator), reduces the risk for HF hospitalization and improves left ventricular (LV) structure and function in patients with NYHA class II and even class I patients with previous HF symptoms. Clearly, these 2 trials followed the "winning formula" in demonstrating consistent beneficial effects in designated end points, with findings that are concordant with earlier data. 10 These results, not unexpectedly, have energized a chorus of investigators echoing the need to expand current guideline indications to consider CRT in patients with mild HF.
It is important to recognize that randomized clinical trials provide validation of a hypothesis. This process of hypothesis testing assumes proper patient selection, appropriate methodology, and reproducible and clinically meaningful outcome measures. Because CRT implantation is invasive, is costly, has a finite time limit (based on battery life and lead integrity), and has a finite benefit scope (only a subset of patients truly yield benefit, even with standard indications of advanced HF), several factors beyond effectiveness and hypothesis validation need to be considered. cannot be generalized to a larger population of mild HF on the basis of 3 observations derived from the published data. First, we believe that a proportion of NYHA class II patients entered into both studies may have more advanced disease than "mild HF." For example, the mean baseline 6-minute walk distances in REVERSE (396 m) and MADIT-CRT (360 m) suggest that many patients were possibly approaching NYHA class III rather than being minimally symptomatic, 11 even though these distances are higher than those observed in prior CRT studies. 1, 12 To give some perspective from the US Carvedilol Trials Programs, the mean baseline 6-minute walk distance for "moderate" NYHA class II-III HF was 360 m (ranging from 150 to 425 m, similar to that in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure [COMPANION] trial), 13 whereas those with "mild" NYHA class II HF demonstrated a mean 6-minute walk distance of 483 m (ranging from 450 to 550 m). 14 Six-minute walk distances were not reported in defibrillator trials, and therefore direct comparisons are not feasible. 15, 16 Patients who are stoic, are young, or have lived with their conditions for a long time may not necessarily consider themselves "symptomatic," even though they may not be able to perform up to their expected aerobic exercise levels. This is particularly true when the label of "NYHA class II" may span across a wide spectrum of disease severity for the purpose of enrollment into a clinical trial. The lack of objective demonstration of functional capacity may limit our interpretation as to whether HF in enrolled subjects was truly mild.
Second, we argue that the discrepancies between NYHA class and 6-minute walk distance in enrolled subjects represent the fact that these patients (and/or the physicians enrolling them into the studies) may not even consider their preexisting condition as "HF" per se in the absence of overt congestion. Unlike most CRT-D recipients, patients who received prophylactic implantable cardioverter-defibrillator implantation after myocardial infarction may not be closely followed by a cardiologist or HF specialist. Their HF signs and symptoms may be subtle and can be overlooked by healthcare providers. These patients are less likely to receive comprehensive patient education or proper disease management regarding dietary and medication compliance because they have yet to develop "congestive" signs and symptoms. Diagnostic data from devices that document intrathoracic impedance trends can often identify such individuals, and many of them on review lacked insight into lifestyle modifications related to HF prevention. 17 Clearly, an approach far less invasive than CRT can easily avert such HF exacerbations.
Our third observation considers another population that was included in both studies: the asymptomatic (NYHA class I) subjects with postinfarction cardiac dysfunction who have a concomitant conduction delay. It is important to recognize that NYHA class I patients in MADIT-CRT (14%) and REVERSE (18%) constitute a relatively small sample size. This population poses significant challenges because clinically, if indeed they are asymptomatic (or minimally symp-tomatic), symptom relief will not be a major goal. Furthermore, long-term outcomes may not be seen until after very prolonged follow-up (from years to even decades), although the burden of procedural risk (especially with reimplantations) and complications may increase over time. In general, NYHA class I subjects are less likely to have LBBB and wide QRS. The fact that neither study showed any benefit in this cohort poses major concerns in advocating use of an invasive procedure with rare but potentially serious risks.
Do the HF Events in the Primary End Point That Were Reduced by CRT Actually Represent Clinical Deterioration of HF?
The benefit of CRT-D in MADIT-CRT was driven predominantly by a significant 41% relative reduction in the risk of a first HF event. It assumes by logical deduction that these incident HF exacerbations are directly related to progression of underlying cardiac dysfunction and dyssynchrony, and the 2 studies provided evidence to support the hypothesis that adding CRT to standard therapy can halt or reverse such disease progression. This finding is supported by the fact that LV pacing itself appears to ameliorate cardiac dysfunction in a subset of patients, 18 and LBBB remains the strongest predictor of normalization of LV function in a large clinical experience. 19 Nevertheless, the assumption that all subjects have the same trajectory of clinical deterioration is unlikely, and therefore the primary end point reduced by CRT may not represent true clinical deterioration of HF. We argue that there may be too much heterogeneity in the patient population included in MADIT-CRT and REVERSE enrollment criteria. This heterogeneity includes the various reasons for HF deterioration, the pace at which deterioration occurs, and the inability to easily identify subsets of patients in whom deterioration occurs because of underlying dyssynchrony. In other words, a "HF event" due to myocardial deterioration may be very different from acute decompensation due to dietary indiscretion or lack of self-help skills. We cannot always distinguish these 2 problems in an individual patient. There may also be a low threshold for seeking help at the hospital, where direct access to care is readily available. Clearly, both arms of the study will be affected by the same factors and confounders in a randomized manner, but this also means that such improvement in a HF event may not directly translate to meaningful long-term benefits and costeffectiveness if optimal medical management and disease management are instituted before or after the HF event.
We cannot neglect the possibility that there is a potential for CRT, when used in mild HF, to disrupt an otherwise compensated state of cardiac insufficiency that is responsible for the relatively mild symptoms to begin with. Although anecdotal, we have followed patients with LBBB and impaired LV systolic function for many years without CRT who have remained asymptomatic or mildly symptomatic on medical therapy. This is particularly true in those with asymptomatic LV systolic dysfunction and an "incidental" finding of LBBB with an otherwise well-compensated enlarged ventricle to preserve stroke volume. Some may have no progression of left LV dysfunction or onset of overt HF symptoms for years. 20, 21 Reverse remodeling with CRT occurs primarily within the first 6 months after implantation and provides strong prognostic benefit in patients with traditional indications. 22 Therefore, the demonstration of reverse remodeling in both MADIT-CRT and REVERSE provides a very strong argument for CRT based on the ability of this intervention to directly improve the biological changes resulting from the pathophysiology of HF. However, reverse remodeling did not occur in all patients despite the intended purpose of restoring synchrony with CRT. In fact, the lack of statistically significant clinical improvement in patients with QRS Ͻ150 ms (Ϸ35% of enrolled subjects in both studies) is consistent in almost all of the trials conducted to date. Furthermore, there was diminished efficacy of CRT observed in patients without LBBB. 7, 23 These observations argue against using a simple criterion of QRS Ն120 ms in selecting patients within a population in whom there is much less tangible risk of morbidity and mortality and therefore much less room for accommodating nonresponders.
Would Delaying CRT Implantation When Symptoms Worsen Be Detrimental?
We argue that the strategy supported by MADIT-CRT and REVERSE may not be superior to one based on CRT "upgrade" when more advanced symptoms ensue. Although the primary outcomes in both MADIT-CRT and REVERSE were met, there are several assumptions in the interpretation of these results. The differences in outcomes assume a time-to-event analysis, which means that at the first occurrence of an "event," an individual is censored as experiencing a bad outcome. In MADIT-CRT, the HF end point included "signs and symptoms consistent with congestive HF that was responsive to intravenous decongestive therapy on an outpatient basis or an augmented decongestive regimen with oral or parenteral medications during an in-hospital stay." 7 It is important to point out that the use of a "softer" end point of HF event is largely statistical in order to inflate the beneficial effects seen with CRT because neither study was adequately powered to identify a statistically significant effect of CRT on the end point of all-cause mortality or HF hospitalizations. The fact that serious adverse events such as all-cause mortality were similar in both arms may justify an alternative approach to delay implantation until more advanced symptoms or disease progression toward traditional indications ensues. Being underpowered to demonstrate clinically relevant end points means that the effect size of the true benefit is limited despite a relative large study population.
Is the Risk of CRT Equal to That of an Implantable Cardioverter-Defibrillator Implantation?
We further argue that consideration of overall unintended consequences related to periprocedural risks and long-term adverse effects of an implanted device is warranted when broadened to a mild HF population. MADIT-CRT and REVERSE enrolled patients who already have the indications for device implantation. Many may claim that device implantation will be inevitable (and will have similar risks) because underutilization of implantable cardioverter-defibrillators in otherwise eligible patients may be associated with poorer outcomes. 24, 25 However, there has been increasing scrutiny regarding the perceived risks of device implantation and complications in a clinical trial versus in clinical practice. This is particularly true when older patients (often excluded from clinical trials) may have a wide range of complications related to device implantation. 26 Seldom discussed are the late complications of device implantations including device infections, lead malfunctions, and inappropriate device programming, 27 all of which can raise concerns in less sick individuals in whom the relative benefits are far lower than in sicker individuals. In the clinical practice setting, adding 1 or even 2 leads can extend procedure time and may directly add to the risk. 28, 29 Furthermore, complication rates due to device changes or reimplantation directly or indirectly can be the result of generator or lead changes. 30 Other factors that may confound outcomes derived from clinical trials include the expertise of the implanting physician 31 or the implantation volume of the institution. 32 Adding a defibrillator-cardioverter device to CRT is a related and sometimes difficult issue because of inappropriate shocks. 27 Although these factors may be less important in patients with advanced HF undergoing CRT, the overall favorable survival rates in a large majority of patients with mild HF are a cause for concern if the initial estimates of risk in regard to CRT rise beyond the observation periods in MADIT-CRT or REVERSE (ie, Ͼ2.5 years on average). Implanting a CRT does not necessarily mean that resynchronization is guaranteed or even appropriate. Even in subjects with the widest QRS and LBBB with a clear indication, technical limitations and suboptimal positions may actually contribute to deterioration. Inappropriate CRT settings may also impair adequate responses and therefore limit the potential benefit after the implantation. In advanced HF, an optimistic estimate of 30% nonresponders to CRT is present and often unpredictable from pre-CRT cardiac characteristics. 33 Appropriate optimization may yield some potential benefit in the setting of a comprehensive HF disease management approach. 34 Like any invasive procedures, the potential to cause poorer rather than better quality of life in the setting of mild HF needs serious justification.
Is the Strategy of Early CRT Implantation Cost-Effective?
We argue that at present we do not know whether early CRT implantation is cost-effective. In the United States, CRT-D devices have a retail price of $20 000 to $25 000 per unit, which does not include the actual implantation procedure or postprocedural care. The potential clinical benefit and/or cost savings with CRT without a defibrillator is also unclear. Although we know that Ϸ70% of patients receiving CRT-D who have advanced HF will improve, this beneficial impact may be less robust in mildly symptomatic patients and will likely take a longer time. Despite the potential that some of the cost of the device could be offset by a reduced hospitalization rate, a comprehensive, rigorous cost-effectiveness evaluation has not yet been performed in these patients with milder HF, especially when not all HF events were adjudicated in the traditional manner.
Is There a Subgroup of Individuals Who May Derive More Benefit?
We concede that some subgroups may benefit from early CRT, which is based on both the degree and pattern of dyssynchrony. On the basis of published reports from MADIT-CRT and REVERSE, those with nonischemic dilated cardiomyopathy and an underlying wide QRS (Ն150 ms) are more likely to have LV remodeling solely as a consequence of the conduction abnormality and are therefore more likely to respond to CRT in terms of reverse remodeling. 19 Clearly, those with QRS Ն150 ms are also more likely to have underlying LBBB than those with QRS Ͻ150 ms. The fact that hemodynamic augmentation can be achieved with biventricular pacing does not mean that they can clinically benefit from CRT. 35 In contrast, those patients with progressive LV remodeling from a myocardial ischemic event who have extensive scar tissue with a corresponding emerging conduction delay secondary to the remodeling process are perhaps less likely to respond to CRT. Before CRT is implanted in minimally symptomatic patients, it would be helpful to know which type of patient is most likely to respond with reverse remodeling in this less advanced setting.
Conclusions
It is no easy task to take on this challenge to argue for holding fast on restrictions to a promising new therapy that many experts strongly believe should have a more expansive indication on the basis of 2 excellent studies. Both MADIT-CRT and REVERSE indicate that significant improvement in cardiac structure and function occurs in mildly symptomatic patients with HF after CRT-D. 8, 23 To expand this therapy to the asymptomatic or mildly symptomatic patient in hopes of forestalling the onset of more severe HF is very tempting. We argue that although it may seem highly intuitive and arguably the right thing to do in carefully selected patients, only more time and experience may unfold the strategy that is truly appropriate. All of the collective data (pooled analysis of MADIT-CRT and REVERSE), including the as yet incomplete Canadian Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT), 36 should probably be analyzed to be certain that the size and direction of the changes in end points are concordant before the guidelines are changed. Even more important and more convincing would be a study with very long-term follow-up, likely beyond 5 to 7 years, including the prospects of reimplantation. We may observe the potential of dramatic reverse cardiac remodeling in a subset of patients (thereby changing the natural history) but simply a delay in the inevitable for others.
If CRT were an oral drug therapy with an acceptable side effect profile for general use (like neurohormonal antagonists), few would argue that, on the basis of 2 large, well-conducted, prospective randomized controlled trials, the evidence is still insufficient. By taking advantage of advanced symptoms as an indication of hemodynamic compromise, clinicians can identify patients who may benefit from hemodynamic augmentation via the implementation of CRT as a corrective therapy for underlying electric dyssynchrony (particularly LBBB). MADIT-CRT and REVERSE demonstrate that in the absence of an objective assessment of functional capacity, self-reported mild clinical signs and symptoms of HF may still identify patients with hemodynamic compromise on the basis of underlying dyssynchrony who may benefit from CRT. We are still searching for the underlying culprit that CRT seeks to correct, and hence those with very wide QRS of the LBBB morphology type (with some but not excessive ventricular remodeling, and particularly with a nonischemic etiology in which excessive scarring has not occurred) will yield the most consistent benefits. This is in contrast to the superficial interpretation of the primary results that imply an "all-inclusive" adoption of an otherwise invasive and costly treatment, at least until proven otherwise.
One potential but untested strategy would be to advocate for CRT with pacing alone in low-risk cases, perhaps with sensors and wireless transmission to monitor HF status, activity levels, and arrhythmia status. These data would essentially provide early warning signs of evolving problems. Taking advantage of evolving technology (while moving from CRT with pacing alone to CRT-D in selected cases over time) is perhaps a more palatable alternative approach than moving to early CRT-D. Such a tiered approach may be worthy of consideration for a randomized trial with a long-term follow-up.
